Dengue Vaccines: Strongly Sought but Not a Reality Just Yet

article has not abstract

Vyšlo v časopise: Dengue Vaccines: Strongly Sought but Not a Reality Just Yet. PLoS Pathog 9(10): e32767. doi:10.1371/journal.ppat.1003551
Kategorie: Pearls
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003551

Souhrn

article has not abstract

Zdroje

1. BhattS, GethingPW, BradyOJ, MessinaJP, FarlowAW, et al. (2013) The global distribution and burden of dengue. Nature 496: 504–507.

2. SuayaJA, ShepardDS, SiqueiraJB, MartelliCT, LumLC, et al. (2009) Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 80: 846–855.

3. KuhnRJ, ZhangW, RossmannMG, PletnevSV, CorverJ, et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717–725.

4. UbolS, HalsteadSB (2010) How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 17: 1829–1835.

5. Rodenhuis-ZybertIA, van der SchaarHM, da Silva VoorhamJM, van der Ende-MetselaarH, LeiH-Y, et al. (2010) Immature dengue virus: a veiled pathogen? PLoS Pathog 6: e1000718 doi:10.1371/journal.ppat.1000718

6. SabinAB, SchlesingerRW (1945) Production of immunity to dengue with virus modified by propagation in mice. Science 101: 640–642.

7. VaughnDW, HokeCHJr, YoksanS, LaChanceR, InnisBL, et al. (1996) Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14: 329–336.

8. ThomasSJ, EckelsKH, CarlettiI, De La BarreraR, DessyF, et al. (2013) A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 88: 73–88.

9. MenR, BrayM, ClarkD, ChanockRM, LaiCJ (1996) Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 70: 3930–3937.

10. DurbinAP, KirkpatrickBD, PierceKK, ElwoodD, LarssonCJ, et al. (2013) A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 207: 957–965.

11. SabchareonA, WallaceD, SirivichayakulC, LimkittikulK, ChanthavanichP, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559–1567.

12. PutnakR, BarvirDA, BurrousJM, DuboisDR, D'AndreaVM, et al. (1996) Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174: 1176–1184.

13. Robert PutnakJ, CollerBA, VossG, VaughnDW, ClementsD, et al. (2005) An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23: 4442–4452.

14. PutnakR, FullerJ, VanderZandenL, InnisBL, VaughnDW (2003) Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am J Trop Med Hyg 68: 469–476.

15. SimmonsM, BurgessT, LynchJ, PutnakR (2010) Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396: 280–288.

16. SunW, EckelsKH, PutnakJR, LyonsAG, ThomasSJ, et al. (2013) Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 207: 700–708.